Skip to main content
. 2022 Aug 4;15(10):2479–2492. doi: 10.1111/cts.13376

FIGURE 1.

FIGURE 1

Trial design. *Primary outcomes will be compared between the subgroup of PMs and IMs in the intervention versus control arm. IM, NM, and PM phenotypes are based on CYP2D6 genotype and use of moderate to strong CYP2D6 inhibitors. EHR, electronic health record; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.